Viking Therapeutics (VKTX) Total Current Liabilities (2014 - 2026)

Viking Therapeutics has disclosed Total Current Liabilities across 13 years of filings, most recently posting $106.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $106.3 million, up 443.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.3 million (up 443.22% YoY), and the FY2025 annual result was $76.7 million, up 179.67% from the prior year.
• Total Current Liabilities came in at $106.3 million for Q1 2026 at Viking Therapeutics, up from $76.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $106.3 million in Q1 2026 to a low of $11.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $21.9 million (2022), against an average of $29.1 million.
• Across the five-year window, Total Current Liabilities plunged 40.28% in 2025 and jumped 443.22% in 2026, its largest moves.
• Viking Therapeutics' Total Current Liabilities stood at $21.9 million in 2022, then fell by 12.81% to $19.1 million in 2023, then jumped by 43.26% to $27.4 million in 2024, then surged by 179.67% to $76.7 million in 2025, then jumped by 38.68% to $106.3 million in 2026.
• The last three Total Current Liabilities figures came in at $106.3 million (Q1 2026), $76.7 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.